NZ597621A - Sustained delivery formulations of risperidone compounds - Google Patents

Sustained delivery formulations of risperidone compounds

Info

Publication number
NZ597621A
NZ597621A NZ59762108A NZ59762108A NZ597621A NZ 597621 A NZ597621 A NZ 597621A NZ 59762108 A NZ59762108 A NZ 59762108A NZ 59762108 A NZ59762108 A NZ 59762108A NZ 597621 A NZ597621 A NZ 597621A
Authority
NZ
New Zealand
Prior art keywords
combination
medicament
risperidone
implant
hydroxyrisperidone
Prior art date
Application number
NZ59762108A
Other languages
English (en)
Inventor
Eric Dadey
Original Assignee
Tolmar Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39496214&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ597621(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Tolmar Therapeutics Inc filed Critical Tolmar Therapeutics Inc
Publication of NZ597621A publication Critical patent/NZ597621A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
NZ59762108A 2007-05-25 2008-02-13 Sustained delivery formulations of risperidone compounds NZ597621A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94034007P 2007-05-25 2007-05-25
PCT/US2008/001928 WO2008153611A2 (en) 2007-05-25 2008-02-13 Sustained delivery formulations of risperidone compounds

Publications (1)

Publication Number Publication Date
NZ597621A true NZ597621A (en) 2013-06-28

Family

ID=39496214

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ59762108A NZ597621A (en) 2007-05-25 2008-02-13 Sustained delivery formulations of risperidone compounds
NZ581862A NZ581862A (en) 2007-05-25 2008-02-13 Injectable subcutaneous formulation comprising risperidone capable of forming a solid, microporous implant in a patient

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ581862A NZ581862A (en) 2007-05-25 2008-02-13 Injectable subcutaneous formulation comprising risperidone capable of forming a solid, microporous implant in a patient

Country Status (11)

Country Link
US (7) US10010612B2 (https=)
EP (2) EP2907524A1 (https=)
JP (3) JP2010531807A (https=)
CN (1) CN101801415B (https=)
AU (1) AU2008262545B2 (https=)
BR (1) BRPI0811319A2 (https=)
CA (1) CA2687979C (https=)
ES (1) ES2562878T3 (https=)
MX (2) MX337286B (https=)
NZ (2) NZ597621A (https=)
WO (1) WO2008153611A2 (https=)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120225033A1 (en) * 2010-11-24 2012-09-06 Durect Corporation Biodegradable Drug Delivery Composition
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
ES2562878T3 (es) 2007-05-25 2016-03-08 Indivior Uk Limited Formulaciones de liberación sostenida de compuestos de risperidona
CN101653422B (zh) * 2008-08-20 2013-03-20 山东绿叶制药有限公司 利培酮缓释微球、其制备方法和用途
CN101584652B (zh) * 2009-06-19 2012-06-20 上海医药集团股份有限公司 利培酮缓释凝胶注射剂及其制备方法
WO2011042453A1 (en) 2009-10-06 2011-04-14 Ascendis Pharma As Subcutaneous paliperidone composition
EP2485767A1 (en) 2009-10-06 2012-08-15 Ascendis Pharma A/S Carrier linked paliperidone prodrugs
US10335366B2 (en) 2010-05-31 2019-07-02 Laboratorios Farmacéuticos Rovi, S.A. Risperidone or paliperidone implant formulation
US10285936B2 (en) 2010-05-31 2019-05-14 Laboratorios Farmacéuticos Rovi, S.A. Injectable composition with aromatase inhibitor
US10350159B2 (en) 2010-05-31 2019-07-16 Laboratories Farmacéuticos Rovi, S.A. Paliperidone implant formulation
US10463607B2 (en) 2010-05-31 2019-11-05 Laboratorios Farmaceutics Rofi S.A. Antipsychotic Injectable Depot Composition
US10881605B2 (en) 2010-05-31 2021-01-05 Laboratorios Farmaceuticos Rovi, S.A. Methods for the preparation of injectable depot compositions
PL2394664T3 (pl) * 2010-05-31 2016-12-30 Preparat przeciwpsychotyczny do wstrzykiwań o przedłużonym uwalnianiu
PL2394663T3 (pl) * 2010-05-31 2022-02-21 Laboratorios Farmaceuticos Rovi, S.A. Kompozycje do wstrzykiwania implantów biodegradowalnych in-situ
GB2513060B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
CN102058517A (zh) * 2010-12-31 2011-05-18 泰州万全医药科技有限公司 一种帕潘立酮缓释剂及其制备方法
HUE046004T2 (hu) 2011-04-25 2020-01-28 Shan Dong Luye Pharm Co Ltd Risperidon nyújtott hatóanyagleadású mikroszféra készítmény
ES2456917T3 (es) * 2011-05-31 2014-04-24 Laboratorios Farmacéuticos Rovi, S.A. Formulación de implante de paliperidona
PT2529756T (pt) 2011-05-31 2021-07-28 Farm Rovi Lab Sa Formulação de implante de risperidona e/ou paliperidona
DE102013011399A1 (de) 2012-07-31 2014-02-06 Amw Gmbh Implantat mit Risperidon
CA2885941A1 (en) * 2012-09-28 2014-04-03 Delpor, Inc. Device and method for sustained release of antipsychotic medications
EA033537B1 (ru) 2013-03-11 2019-10-31 Durect Corp Инъекционная композиция с контролируемым высвобождением, содержащая жидкий носитель с высокой вязкостью
US20140308352A1 (en) 2013-03-11 2014-10-16 Zogenix Inc. Compositions and methods involving polymer, solvent, and high viscosity liquid carrier material
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
US20170266112A1 (en) 2014-06-11 2017-09-21 Massachusetts Institute Of Technology Residence structures and related methods
NZ727659A (en) 2014-06-11 2021-12-24 Massachusetts Inst Technology Residence structures and related methods
CA3015557C (en) 2014-11-07 2019-07-16 Indivior Uk Limited The use of sustained-release buprenorphine formulations for the treatment of pain or opioid use disorders
CN104398474A (zh) * 2014-11-21 2015-03-11 内蒙古医科大学附属医院 一种利培酮鼻用凝胶剂及其制备方法
EP3288604B1 (en) 2015-05-01 2021-11-17 Massachusetts Institute of Technology Triggerable shape memory induction devices
EP3352735B1 (en) 2015-09-21 2023-08-30 Teva Pharmaceuticals International GmbH Sustained release olanzapine formulations
US20190015415A1 (en) * 2015-09-30 2019-01-17 Indivior Uk Limited Methods for treating schizophrenia
US11576859B2 (en) 2015-10-23 2023-02-14 Lyndra Therapeutics, Inc. Gastric residence systems for sustained release of therapeutic agents and methods of use thereof
US20200155449A1 (en) 2015-11-16 2020-05-21 Medincell Method for morselizing and/or targeting pharmaceutically active principles to synovial tissue
WO2017100367A1 (en) 2015-12-08 2017-06-15 Lyndra, Inc. Geometric configurations for gastric residence systems
WO2017119928A1 (en) * 2016-01-08 2017-07-13 Abon Pharmaceuticals, Llc Long acting injectable formulations
CN109310639A (zh) 2016-05-27 2019-02-05 林德拉有限公司 用于胃驻留系统的材料结构
JP2019532947A (ja) 2016-09-30 2019-11-14 リンドラ，インコーポレイティド アダマンタン系薬物の持続的送達のための胃内滞留システム
WO2018127270A1 (en) * 2017-01-04 2018-07-12 Pharmathen S.A. Process for preparing biodegradable polymers of high molecular weight
WO2018151849A1 (en) 2017-02-17 2018-08-23 Privo Technologies, Inc. Particle-based multi-layer therapeutic delivery device and method
WO2018172850A1 (en) 2017-03-20 2018-09-27 Teva Pharmaceuticals International Gmbh Sustained release olanzapine formulaitons
US10478403B1 (en) 2017-05-03 2019-11-19 Privo Technologies, Inc. Intraoperative topically-applied non-implantable rapid release patch
CA3066658A1 (en) 2017-06-09 2018-12-13 Lyndra, Inc. Gastric residence systems with release rate-modulating films
US10646484B2 (en) 2017-06-16 2020-05-12 Indivior Uk Limited Methods to treat opioid use disorder
JP7105156B2 (ja) * 2017-09-20 2022-07-22 花王株式会社 染毛方法
US20190117573A1 (en) * 2017-10-19 2019-04-25 Hyalo Technologies, LLC Composition and method of preparation of risperidone extended release preparation
KR20260007295A (ko) 2018-05-24 2026-01-13 셀라니즈 이브이에이 퍼포먼스 폴리머스 엘엘씨 거대 분자 약물 화합물의 지속적인 방출을 위한 이식가능 장치
EP3803866A4 (en) 2018-05-24 2022-03-16 Nureva Inc. METHOD, APPARATUS, AND COMPUTER READABLE MATERIALS FOR MANAGING SEMI-CONSTANT (PERSISTENT) SOUND SOURCES IN MICROPHONE CATCH/HOME AREAS
MX2020012459A (es) 2018-05-24 2021-04-28 Celanese Eva Performance Polymers Llc Dispositivo implantable para liberacion sostenida de un compuesto de farmaco macromolecular.
PE20210047A1 (es) 2018-06-12 2021-01-08 Farm Rovi Lab Sa Composicion inyectable
WO2020154315A1 (en) * 2019-01-22 2020-07-30 Indivior Uk Limited Methods for treating schizophrenia
MX2022003051A (es) 2019-09-13 2022-06-14 Medincell S A Formulaciones para la administracion de farmacos.
CN114938646B (zh) * 2019-12-05 2026-03-27 费森尤斯卡比有限责任公司 分析地加瑞克及其相关产物的方法
CA3166633A1 (en) * 2020-01-03 2021-07-08 Privo Technologies, Inc. Systems and pharmaceutical compositions for treatment by direct injection of a targeted population of cells
EP4221688A1 (en) * 2020-09-30 2023-08-09 Tolmar International Limited Biodegradable polymer and solvent compositions and systems for extended storage and delivery of active pharmaceutical ingredients
US20240100012A1 (en) 2021-01-18 2024-03-28 Mark Hasleton Pharmaceutical dosage form
BR112023022439A2 (pt) 2021-04-26 2023-12-26 Celanese Eva Performance Polymers Llc Dispositivo implantável para liberação sustentada de um composto de fármaco macromolecular
CN113267579B (zh) * 2021-05-18 2022-08-30 中南民族大学 一种监测利培酮血药浓度的方法
KR20240041285A (ko) 2021-06-01 2024-03-29 프리보 테크놀로지스, 인코포레이티드 향상된 2단계 미세입자 기반 국소 치료제 전달 시스템
CA3218153A1 (en) * 2021-06-30 2023-01-05 Soumya Rahima BENHABBOUR Injectable, biodegradable and removable polymer based drug suspension for ultra-long-acting drug delivery
JP2024529009A (ja) 2021-07-06 2024-08-01 マーク・ヘースルトン セロトニン再取り込み阻害剤離脱症候群の治療
US12318387B2 (en) 2021-07-16 2025-06-03 Laboratorios Farmaceuticos Rovi, S.A. Method of treating acute exacerbation of schizophrenia with long-acting injectable depot composition
US12594236B2 (en) 2021-07-16 2026-04-07 Laboratorios Farmaceuticos Rovi, S.A. Method of treating acute exacerbation of schizophrenia with long-acting injectable depot composition
TW202313047A (zh) 2021-09-21 2023-04-01 西班牙商禾霏藥品實驗室有限公司 抗精神病可注射儲積型組合物
CA3248062A1 (en) 2022-05-18 2025-07-10 Laboratorios Farmacéuticos Rovi, S.A. Extended-release injectable compositions intended for use in treatment with risperidone in conjunction with CYP2D6 enzyme inhibitors
TW202523334A (zh) * 2023-12-13 2025-06-16 大陸商長春金賽藥業有限責任公司 原位皮下植入的女性激素調節組合物及其製備方法和用途
CN119950530B (zh) * 2025-01-24 2025-12-05 山东新时代药业有限公司 一种包含他莫昔芬与人参皂苷的纳米乳及其制备方法

Family Cites Families (209)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB806876A (en) 1956-02-16 1959-01-07 Wellcome Found Improvements in and relating to disposable hypodermic injection devices
GB873526A (en) 1957-08-14 1961-07-26 Upjohn Co Fluid compositions comprising (acetyl-salicylic acid)-anhydride
GB887872A (en) 1958-06-25 1962-01-24 Upjohn Co Improvements in or relating to pharmaceutical preparations
DE1467938C3 (de) 1964-05-22 1973-12-20 F. Hoffmann-La Roche & Co Ag, Basel (Schweiz) Wasserdispergierbares Arzneipräparat für Tiere
JPS5078634A (https=) 1973-11-16 1975-06-26
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4530840A (en) 1982-07-29 1985-07-23 The Stolle Research And Development Corporation Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents
US4906474A (en) 1983-03-22 1990-03-06 Massachusetts Institute Of Technology Bioerodible polyanhydrides for controlled drug delivery
US4622219A (en) 1983-06-17 1986-11-11 Haynes Duncan H Method of inducing local anesthesia using microdroplets of a general anesthetic
US4725442A (en) 1983-06-17 1988-02-16 Haynes Duncan H Microdroplets of water-insoluble drugs and injectable formulations containing same
US4891225A (en) 1984-05-21 1990-01-02 Massachusetts Institute Of Technology Bioerodible polyanhydrides for controlled drug delivery
US4588580B2 (en) 1984-07-23 1999-02-16 Alaz Corp Transdermal administration of fentanyl and device therefor
US4534974A (en) 1984-07-31 1985-08-13 Carter-Wallace, Inc. Pharmaceutical compositions with codeine
US4626539A (en) 1984-08-10 1986-12-02 E. I. Dupont De Nemours And Company Trandermal delivery of opioids
US4573995A (en) 1984-10-09 1986-03-04 Alza Corporation Transdermal therapeutic systems for the administration of naloxone, naltrexone and nalbuphine
US4804663A (en) * 1985-03-27 1989-02-14 Janssen Pharmaceutica N.V. 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
GB8522453D0 (en) 1985-09-11 1985-10-16 Lilly Industries Ltd Chewable capsules
JPS62298530A (ja) 1986-06-16 1987-12-25 Otsuka Pharmaceut Co Ltd 坐薬用医薬組成物
IT1198449B (it) 1986-10-13 1988-12-21 F I D I Farmaceutici Italiani Esteri di alcoli polivalenti di acido ialuronico
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5702716A (en) 1988-10-03 1997-12-30 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
US5008110A (en) 1988-11-10 1991-04-16 The Procter & Gamble Company Storage-stable transdermal patch
CA2002299A1 (en) 1988-11-10 1990-05-10 Eugene G. Drust Compositions for the transdermal delivery of buprenorphine salts
US5026556A (en) 1988-11-10 1991-06-25 Norwich Eaton Pharmaceuticals, Inc. Compositions for the transdermal delivery of pharmaceutical actives
US5324519A (en) * 1989-07-24 1994-06-28 Atrix Laboratories, Inc. Biodegradable polymer composition
US5487897A (en) 1989-07-24 1996-01-30 Atrix Laboratories, Inc. Biodegradable implant precursor
DE3927113C2 (de) 1989-08-17 1993-11-25 Dolorgiet Gmbh & Co Kg Mittel zur Behandlung von schweren Schmerzzuständen und Verfahren zu ihrer Herstellung
US5096715A (en) 1989-11-20 1992-03-17 Alko Ltd. Method and means for treating alcoholism by extinguishing the alcohol-drinking response using a transdermally administered opiate antagonist
US5558880A (en) * 1989-12-22 1996-09-24 Janssen Pharmaceutica Inc. Pharmaceutical and other dosage forms
US5660851A (en) 1989-12-26 1997-08-26 Yissum Research Development Company Of The Hebrew Univ. Of Jerusalem Ocular inserts
ATE164080T1 (de) 1990-05-10 1998-04-15 Bechgaard Int Res Pharmazeutische zubereitung enthaltend n- glykofurole und n-äthylenglykole
US5069909A (en) 1990-06-20 1991-12-03 Cygnus Therapeutic Systems Transdermal administration of buprenorphine
JPH0456736U (https=) 1990-09-14 1992-05-15
US5149543A (en) 1990-10-05 1992-09-22 Massachusetts Institute Of Technology Ionically cross-linked polymeric microcapsules
AU668679B2 (en) 1991-02-18 1996-05-16 Transdermal Technologies Pty Limited Composition for use in transdermal administration
JP3145742B2 (ja) 1991-09-19 2001-03-12 日東電工株式会社 ゴム系感圧性接着剤とその接着シ―ト
AU2605592A (en) * 1991-10-15 1993-04-22 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
WO1993023019A1 (en) 1992-05-11 1993-11-25 Sri International Transdermal drug delivery systems and related compositions and methods of use
DE69327542T2 (de) 1992-11-17 2000-07-06 Yoshitomi Pharmaceutical Industries, Ltd. Ein antipsychotikum enthaltende mikrokugel zur verzögerten freisetzung und verfahren für ihre herstellung
TW376319B (en) 1993-04-28 1999-12-11 Janssen Pharmaceutica Nv Pharmaceutical composition containing risperidone pamoate and having a long acting activity for treating psychoses induced by the release of dopamine
JP2651106B2 (ja) 1993-06-28 1997-09-10 大同鋼板株式会社 金属屋根材の葺設構造及びその葺設方法
NZ260909A (en) 1993-07-05 1995-04-27 Takeda Chemical Industries Ltd Production of sustained release preparation by allowing a water-soluble polypeptide to permeate into a biodegradable matrix in an aqueous solution
US5643605A (en) 1993-10-25 1997-07-01 Genentech, Inc. Methods and compositions for microencapsulation of adjuvants
EP2283821A1 (en) 1993-11-19 2011-02-16 Alkermes, Inc. Preparation of biodegradable microparticles containing a biologically active agent
CN1074923C (zh) * 1993-11-19 2001-11-21 詹森药业有限公司 微囊密封的3-哌啶基取代的1,2-苯并异唑类和1,2-苯并异噻唑类
JP4259610B2 (ja) 1994-04-08 2009-04-30 キューエルティー・ユーエスエイ・インコーポレーテッド 液体デリバリー組成物
US5453425A (en) * 1994-07-11 1995-09-26 Janssen Pharmaceutica N.V. Risperidone oral formulation
AU4652596A (en) 1995-01-09 1996-07-31 Atrix Laboratories, Inc. Liquid polymer delivery system
JP3274579B2 (ja) 1995-01-12 2002-04-15 住友製薬株式会社 脳血管障害に伴う精神症候治療剤
US6413536B1 (en) 1995-06-07 2002-07-02 Southern Biosystems, Inc. High viscosity liquid controlled delivery system and medical or surgical device
EP1006935B1 (en) 1995-06-07 2005-01-26 Southern Biosystems, Inc. High viscosity liquid controlled delivery system
US7833543B2 (en) 1995-06-07 2010-11-16 Durect Corporation High viscosity liquid controlled delivery system and medical or surgical device
US5968542A (en) 1995-06-07 1999-10-19 Southern Biosystems, Inc. High viscosity liquid controlled delivery system as a device
US5747058A (en) 1995-06-07 1998-05-05 Southern Biosystems, Inc. High viscosity liquid controlled delivery system
US5736152A (en) 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
US6004969A (en) 1996-04-15 1999-12-21 National Science Council Transdermal delivery of buprenorphine preparations
ATE357218T1 (de) 1996-05-07 2007-04-15 Alkermes Inc Micropartikel
US5792477A (en) 1996-05-07 1998-08-11 Alkermes Controlled Therapeutics, Inc. Ii Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent
JP4346696B2 (ja) 1996-05-28 2009-10-21 久光製薬株式会社 経皮治療用装置
DE69710460T2 (de) * 1996-06-17 2002-10-02 Janssen Pharmaceutica N.V., Beerse Bikonvexe, rasch desintegrierende verabreichungsformen
JP4642946B2 (ja) 1996-12-20 2011-03-02 アルザ コーポレイション ゲル組成物および方法
DE19701912C1 (de) 1997-01-10 1998-05-14 Jenapharm Gmbh Injizierbares Implantat
US5948787A (en) 1997-02-28 1999-09-07 Alza Corporation Compositions containing opiate analgesics
IT1292396B1 (it) 1997-06-23 1999-02-08 Lisapharma Spa Cerotto dermico avente elevata resistenza meccanica,flessibilita' trasparenza e conducibilita' elettrica nel trattamento di affezioni
US6622036B1 (en) 2000-02-09 2003-09-16 Cns Response Method for classifying and treating physiologic brain imbalances using quantitative EEG
KR100550689B1 (ko) 1998-02-10 2006-02-08 제너럴 일렉트릭 캄파니 가스 터빈의 연소 시스템용 버너 및 연료와 공기의 예비혼합 방법
US6733767B2 (en) 1998-03-19 2004-05-11 Merck & Co., Inc. Liquid polymeric compositions for controlled release of bioactive substances
US7208011B2 (en) 2001-08-20 2007-04-24 Conor Medsystems, Inc. Implantable medical device with drug filled holes
US6261583B1 (en) 1998-07-28 2001-07-17 Atrix Laboratories, Inc. Moldable solid delivery system
US6703047B2 (en) 2001-02-02 2004-03-09 Incept Llc Dehydrated hydrogel precursor-based, tissue adherent compositions and methods of use
US6143314A (en) 1998-10-28 2000-11-07 Atrix Laboratories, Inc. Controlled release liquid delivery compositions with low initial drug burst
US6565874B1 (en) 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
US6355657B1 (en) 1998-12-30 2002-03-12 Atrix Laboratories, Inc. System for percutaneous delivery of opioid analgesics
US6194006B1 (en) * 1998-12-30 2001-02-27 Alkermes Controlled Therapeutics Inc. Ii Preparation of microparticles having a selected release profile
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6383471B1 (en) 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US6291013B1 (en) 1999-05-03 2001-09-18 Southern Biosystems, Inc. Emulsion-based processes for making microparticles
DE19923551A1 (de) 1999-05-21 2000-11-30 Lohmann Therapie Syst Lts Pharmazeutisches Präparat mit dem Wirkstoff Diamorphin und seine Verwendung in einem Verfahren zur Behandlung der Opiatsucht
US6461631B1 (en) 1999-11-16 2002-10-08 Atrix Laboratories, Inc. Biodegradable polymer composition
ATE355824T1 (de) 2000-01-11 2007-03-15 Roland Bodmeier Kit zur implantation enthaltend eine trägerphase und ein lösungsmittel
KR100393478B1 (ko) 2000-03-29 2003-08-06 주식회사종근당 자가유화 매트릭스형 경점막·경피흡수제제
DE60009959T2 (de) 2000-05-05 2005-03-31 Rpg Life Sciences Limited Verfahren zur herstellung von antipsychotischem 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4h-pyrido[1,2-a]pyrimidin-4-on
US6264987B1 (en) * 2000-05-19 2001-07-24 Alkermes Controlled Therapeutics Inc. Ii Method for preparing microparticles having a selected polymer molecular weight
US6495164B1 (en) 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
NZ523385A (en) 2000-06-28 2005-09-30 Atul J Biodegradable vehicles and BAS-loaded delivery systems for use as biodegradable fillers and/or spacers, e.g. artificial skin
DE10035889A1 (de) 2000-07-24 2002-02-14 Lohmann Therapie Syst Lts Medizinischer Haftkleber mit einem Gehalt an Zucker-Estern
PL365608A1 (en) 2000-08-14 2005-01-10 Teva Pharmaceutical Industries Ltd. Preparation of risperidone
DE10044545A1 (de) 2000-09-05 2002-04-04 Roland Bodmeier Retardpartikeldispersion
IT250575Y1 (it) 2000-10-10 2003-09-24 Gimatic Spa Sistema di guida registrabile per griffe di pinze azionate da unfluido
WO2002038185A2 (en) 2000-11-13 2002-05-16 Atrix Laboratories, Inc. Injectable sustained release delivery system with loperamide
EP1335704A2 (en) 2000-11-16 2003-08-20 Durect Corporation Implant dosage form and use thereof for the delivery of a cholesterol lowering agent
ATE427760T1 (de) 2001-02-23 2009-04-15 Genentech Inc Erodierbare polymere zur injektion
US20040018238A1 (en) 2001-02-26 2004-01-29 Shukla Atul J Biodegradable vehicles and delivery systems of biolgically active substances
EP1379197A4 (en) 2001-03-23 2009-06-03 Durect Corp DISPOSAL OF MEDICINAL PRODUCTS OF DELAYED RELEASE DEVICES IMPLANTED IN MYOKARD TISSUE OR PER ICARDROOM
US6558702B2 (en) * 2001-04-13 2003-05-06 Alkermes Controlled Therapeutics, Inc. Method of modifying the release profile of sustained release compositions
GB0112324D0 (en) 2001-05-21 2001-07-11 Croda Int Plc Compounds
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
JP2003063954A (ja) 2001-08-24 2003-03-05 Saitama Daiichi Seiyaku Kk リザーバー型貼付剤
DE60239952D1 (de) 2001-11-14 2011-06-16 Durect Corp Injizierbare depotzusammensetzungen und deren verwendung
EP1446101B1 (en) 2001-11-14 2011-03-23 Durect Corporation Catheter injectable depot compositions and uses thereof
JP5170935B2 (ja) 2001-11-14 2013-03-27 デュレクト コーポレーション 注入可能なデポー組成物
US20040258731A1 (en) 2001-11-21 2004-12-23 Tsuyoshi Shimoboji Preparation approriate for cartilage tissue formation
EP1485066B1 (fr) 2002-03-12 2016-09-21 Ethypharm Composition a proprietes gelifiantes destinee a la delivrance prolongee de substances bio-actives
US7041320B1 (en) 2002-05-31 2006-05-09 Biotek, Inc. High drug loaded injectable microparticle compositions and methods of treating opioid drug dependence
MY139059A (en) 2002-06-24 2009-08-28 Alza Corp Reusable, spring driven autoinjector
AR039729A1 (es) 2002-06-25 2005-03-09 Alza Corp Formulaciones de deposito de corta duracion
US20040003401A1 (en) 2002-06-27 2004-01-01 Koninklijke Philips Electronics N.V. Method and apparatus for using cluster compactness as a measure for generation of additional clusters for stereotyping programs
WO2004011065A1 (en) 2002-07-31 2004-02-05 Alza Corporation Injection device providing automatic needle retraction
CN1684663A (zh) 2002-07-31 2005-10-19 阿尔萨公司 可注射的多模式聚合物储库组合物以及其用途
AU2003256006A1 (en) 2002-08-30 2004-03-19 Sunil Sadanand Nadkarni Improved process for preparation of risperidone
EP1556091A1 (en) 2002-10-04 2005-07-27 Elan Pharma International Limited Gamma irradiation of solid nanoparticulate active agents
US20120225033A1 (en) 2010-11-24 2012-09-06 Durect Corporation Biodegradable Drug Delivery Composition
KR20040034996A (ko) 2002-10-18 2004-04-29 한미약품 주식회사 리스페리돈의 개선된 제조방법
DE10250084A1 (de) 2002-10-25 2004-05-06 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
RU2310450C2 (ru) 2002-10-25 2007-11-20 Пфайзер Продактс Инк. Новые депо-препараты для инъекций
RU2355385C2 (ru) 2002-11-06 2009-05-20 Алза Корпорейшн Композиции пролонгированного действия с контролируемым высвобождением
ATE482695T1 (de) 2002-12-13 2010-10-15 Durect Corp Orale darreichungsform mit flüssigen hochviskosen trägersystemen
AU2003297087B2 (en) 2003-02-04 2009-06-11 Philip Morris Products S.A. Aerosol formulations and aerosol delivery of buspirone, buprenorphine, triazolam, cyclobenzaprine and zolpidem
WO2004084868A1 (en) 2003-03-26 2004-10-07 Egalet A/S Morphine controlled release system
WO2004094414A1 (en) 2003-04-22 2004-11-04 Synthon B.V. Water soluble salts of risperidone
CA2527664A1 (en) 2003-05-30 2004-12-16 Alza Corporation Implantable elastomeric depot compositions, uses thereof and method of manufacturing
DK1635875T3 (da) 2003-06-26 2009-01-12 Psivida Inc In-situ-geldannende lægemiddeladministrationssystem
TWI357815B (en) 2003-06-27 2012-02-11 Euro Celtique Sa Multiparticulates
FI20045223L (fi) 2004-06-15 2005-12-16 Bioretec Oy Monitoiminen biohajoava komposiitti ja kirurginen implantti, joka käsittää mainitun komposiitin
US20050032781A1 (en) * 2003-08-06 2005-02-10 Elliot Ehrich Methods for administering active agents to CYP 2D6 sensitive patients
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
JP2007504256A (ja) 2003-09-01 2007-03-01 メイン・ファ−マ・インタ−ナショナル・プロプライエタリ−・リミテッド 生物活性剤の送達のための組成物及び方法
WO2005037949A2 (en) 2003-10-07 2005-04-28 Chrysalis Technologies Incorporated Aerosol formulations of butalbital, lorazepam, ipratropium, baclofen, morphine and scopolamine
US20050281879A1 (en) 2003-11-14 2005-12-22 Guohua Chen Excipients in drug delivery vehicles
US20050106214A1 (en) 2003-11-14 2005-05-19 Guohua Chen Excipients in drug delivery vehicles
US7201920B2 (en) 2003-11-26 2007-04-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
EP1689465A4 (en) 2003-12-05 2011-10-12 Zogenix Inc DEVICE FOR DELIVERY OF A NEEDLELESS INJECTOR USED FOR DRUG DELIVERY
AU2004313245B2 (en) 2003-12-30 2011-04-14 Durect Corporation Polymeric implants, preferably containing a mixture of PEG and PLG, for controlled release of active agents, preferably a GNRH
AU2006269927B2 (en) 2004-01-12 2013-05-16 The Trustees Of The University Of Pennsylvania Drug-containing implants and methods of use thereof
CA2553254C (en) 2004-01-12 2013-12-17 The Trustees Of The University Of Pennsylvania Long-term delivery formulations and methods of use thereof
US8221778B2 (en) 2005-01-12 2012-07-17 The Trustees Of The University Of Pennsylvania Drug-containing implants and methods of use thereof
US8329203B2 (en) * 2004-01-12 2012-12-11 The Trustees Of The University Of Pennsylvania Drug-containing implants and methods of use thereof
US20100016267A1 (en) 2004-03-15 2010-01-21 Felix Theeuwes Pharmaceutical compositions for administraton to a sinus
IS7290A (is) 2004-05-28 2005-11-29 Actavis Group Lyfjasamsetningar sem innihalda risperidone
US8236292B2 (en) 2004-06-04 2012-08-07 Camurus Ab Liquid depot formulations
EP1604693A1 (en) 2004-06-09 2005-12-14 Scil Technology GmbH In situ forming scaffold, its manufacturing and use
GB2418854B (en) 2004-08-31 2009-12-23 Euro Celtique Sa Multiparticulates
AU2005284908B2 (en) 2004-09-13 2011-12-08 Morningside Venture Investments Limited Biosynchronous transdermal drug delivery
US8313763B2 (en) 2004-10-04 2012-11-20 Tolmar Therapeutics, Inc. Sustained delivery formulations of rapamycin compounds
MX2007003789A (es) 2004-10-04 2007-07-20 Qlt Usa Inc Suministro ocular de formulaciones polimericas para suministro.
SI1814531T1 (sl) 2004-10-21 2010-10-29 Durect Corp Transdermalni dostavni sistem
RS53890B1 (sr) * 2004-11-10 2015-08-31 Tolmar Therapeutics, Inc. Stabilizovan polimerni sistem za isporuku
GB2420976B (en) 2004-11-19 2006-12-20 Zvi Finkelstein Therapeutic implant
TWI369218B (en) 2004-12-14 2012-08-01 Novartis Ag In situ forming implant for animals
JP2008524235A (ja) 2004-12-15 2008-07-10 キューエルティー ユーエスエー，インコーポレイテッド． オクトレオチド化合物の徐放性送達処方物
WO2006063430A1 (en) 2004-12-16 2006-06-22 Miv Therapeutics Inc. Multi-layer drug delivery device and method of manufacturing same
US9415034B2 (en) 2005-01-05 2016-08-16 National Defense Medical Center Inhibitors and enhancers of uridine diphosphate-glucuronosyltransferase 2B (UGT2B)
US9168216B2 (en) 2005-06-17 2015-10-27 Vital Health Sciences Pty. Ltd. Carrier comprising one or more di and/or mono-(electron transfer agent) phosphate derivatives or complexes thereof
US20070020186A1 (en) 2005-07-22 2007-01-25 Alpex Pharma S.A. Solid dosage formulations of narcotic drugs having improved buccal adsorption
EP1912627B1 (en) 2005-08-11 2016-08-10 Promedon S.A. Composition comprising polymeric, water-insoluble, anionic particles, processes and uses
US8852638B2 (en) * 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
CA2627292C (en) 2005-10-26 2012-04-17 Banner Pharmacaps, Inc. Hydrophilic vehicle-based dual controlled release matrix system
WO2007084460A2 (en) 2006-01-18 2007-07-26 Qps, Llc Pharmaceutical compositions with enhanced stability
US20090022798A1 (en) 2007-07-20 2009-01-22 Abbott Gmbh & Co. Kg Formulations of nonopioid and confined opioid analgesics
US8765178B2 (en) 2006-07-19 2014-07-01 Watson Laboratories, Inc. Controlled release formulations and associated methods
KR20090060448A (ko) 2006-09-25 2009-06-12 코닌클리케 필립스 일렉트로닉스 엔.브이. 음향 신호를 발생시키기 위한 음향 부재를 포함하는 온수 주전자
CA2664986C (en) 2006-10-02 2015-09-22 Labtec Gesellschaft Fuer Technologische Forschung Und Entwicklung Mbh Non-mucoadhesive film dosage forms
US20100098735A1 (en) 2006-10-05 2010-04-22 Rajesh Jain Injectable depot compositions and its process of preparation
US8076448B2 (en) 2006-10-11 2011-12-13 Tolmar Therapeutics, Inc. Preparation of biodegradable polyesters with low-burst properties by supercritical fluid extraction
PL2079767T3 (pl) 2006-10-11 2015-05-29 Tolmar Therapeutics Inc Wytwarzanie biodegradowalnych poliestrów z właściwościami niskiego wyrzutu przez ekstrakcję płynem nadkrytycznym
GB0620661D0 (en) 2006-10-18 2006-11-29 Pharmasol Ltd Novel compounds
DK3660073T3 (da) 2007-02-15 2023-09-18 Tolmar International Ltd Poly(lactid-co-glycolid) med lav sprængning
KR101521989B1 (ko) 2007-03-02 2015-05-28 테이카 세이야쿠 가부시키가이샤 경피흡수 의약조성물, 의약조성물 저장유닛 및 이것을 이용하는 경피흡수제제
CA2682848A1 (en) 2007-04-03 2008-10-16 Trimeris, Inc. Novel formulations for delivery of antiviral peptide therapeutics
EP2167039B1 (en) 2007-05-18 2016-09-28 Durect Corporation Improved depot formulations
ES2562878T3 (es) * 2007-05-25 2016-03-08 Indivior Uk Limited Formulaciones de liberación sostenida de compuestos de risperidona
CA2699172C (en) 2007-09-03 2016-05-17 Nanotherapeutics, Inc Compositions and methods for delivery of poorly soluble drugs
DK2200588T3 (da) 2007-09-25 2019-07-01 Solubest Ltd Sammensætninger, som omfatter lipofile aktive forbindelser, og fremgangsmåde til fremstilling deraf
EP2219622A1 (en) 2007-12-06 2010-08-25 Durect Corporation Methods useful for the treatment of pain, arthritic conditions, or inflammation associated with a chronic condition
FR2926996B1 (fr) 2008-01-31 2013-06-21 Ethypharm Sa Composition pharmaceutique a proprietes gelifiantes contenant un derive de tyrosine
EP2244679A4 (en) 2008-02-08 2013-10-09 Qps Llc NON-POLYMERIC COMPOSITIONS FOR CONTROLLED MEDICINAL PRODUCTION
WO2009100216A1 (en) 2008-02-08 2009-08-13 Qps Llc Composition for sustained release delivery of proteins or peptides
JP5286850B2 (ja) 2008-03-14 2013-09-11 大日本印刷株式会社 液体用紙容器用包装材料およびその包装材料から製造される液体用紙容器
JP2011515495A (ja) 2008-03-26 2011-05-19 オールトランツ インコーポレイティド オピエートアゴニスト及びアゴニスト−アンタゴニストの乱用抑制経皮製剤
HRP20150350T1 (hr) 2008-06-03 2015-05-08 Tolmar Therapeutics, Inc. Tekuä†i pripravak koji sadrži biokompatibilne pripravke oligomer-polimer
WO2009148580A2 (en) 2008-06-03 2009-12-10 Qlt Usa, Inc. Controlled release copolymer formulation with improved release kinetics
US8128951B2 (en) 2008-09-15 2012-03-06 Cv Ingenuity Corp. Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens
US8257722B2 (en) 2008-09-15 2012-09-04 Cv Ingenuity Corp. Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens
US8114429B2 (en) 2008-09-15 2012-02-14 Cv Ingenuity Corp. Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens
SG175160A1 (en) 2009-04-23 2011-11-28 Londonpharma Ltd Sublingual pharmaceutical composition comprising a neutral oil
RU2554740C2 (ru) 2009-05-01 2015-06-27 Апталис Фарматек, Инк. Композиции перорально распадающихся таблеток, содержащие комбинации высоко- и низкодозовых лекарственных средств
NZ597283A (en) 2009-06-24 2013-07-26 Egalet Ltd Controlled release formulations
FR2949061B1 (fr) 2009-08-12 2013-04-19 Debregeas Et Associes Pharma Microgranules flottants
PT2501413T (pt) 2009-11-18 2019-07-10 Nektar Therapeutics Formas de sal de ácido de conjugados de polímero-fármaco
US20130023553A1 (en) 2010-01-12 2013-01-24 Nektar Therapeutics Pegylated opioids with low potential for abuse and side effects
CN102821775B (zh) 2010-03-15 2014-10-22 益普生制药股份有限公司 生长激素促分泌素受体配体的药物组合物
US20110230816A1 (en) 2010-03-18 2011-09-22 Tyco Healthcare Group Lp Gels for Transdermal Delivery
PL2394664T3 (pl) 2010-05-31 2016-12-30 Preparat przeciwpsychotyczny do wstrzykiwań o przedłużonym uwalnianiu
PL2394663T3 (pl) 2010-05-31 2022-02-21 Laboratorios Farmaceuticos Rovi, S.A. Kompozycje do wstrzykiwania implantów biodegradowalnych in-situ
WO2011161531A1 (en) 2010-06-24 2011-12-29 Torrent Pharmaceuticals Limited Pharmaceutical composition containing goserelin for in-situ implant
ES2566828T3 (es) 2010-09-21 2016-04-15 Purdue Pharma L.P. Análogos de buprenorfina como agonistas y/o antagonistas del receptor opioide
AU2011331511C1 (en) 2010-11-17 2018-01-18 Hexal Ag Transdermal therapeutic system comprising buprenorphine
AP2013006939A0 (en) 2010-11-26 2013-06-30 Univ Witwatersrand Jhb A drug delivery device
PT2529756T (pt) 2011-05-31 2021-07-28 Farm Rovi Lab Sa Formulação de implante de risperidona e/ou paliperidona
EA201491164A1 (ru) 2011-12-12 2014-10-30 ЭлТиЭс ЛОМАНН ТЕРАПИ-ЗЮСТЕМ АГ Трансдермальная система доставки
US9468599B2 (en) 2011-12-27 2016-10-18 Cmpd Licensing, Llc Composition and method for compounded therapy
US20140134261A1 (en) 2012-08-21 2014-05-15 Trinity Laboratories, Inc. Pharmaceutical Compositions Comprising Capsaicin Esters for Treating Pain and Cold Sores
RU2513514C1 (ru) 2012-11-23 2014-04-20 Общество с ограниченной ответственностью "НПК "Трифарма" Фармацевтическая композиция, содержащая налбуфина гидрохлорид, ее применение для лечения болевого синдрома средней и высокой интенсивности и способ получения фармацевтической композиции
CN103142458B (zh) 2013-01-22 2015-09-09 莱普德制药有限公司 无成瘾性镇痛缓释递药系统的组方与制备方法
US20140308352A1 (en) 2013-03-11 2014-10-16 Zogenix Inc. Compositions and methods involving polymer, solvent, and high viscosity liquid carrier material
EA033537B1 (ru) 2013-03-11 2019-10-31 Durect Corp Инъекционная композиция с контролируемым высвобождением, содержащая жидкий носитель с высокой вязкостью
US9393211B2 (en) 2013-03-15 2016-07-19 Oakwood Laboratories LLC High drug load buprenorphine microspheres and method of producing same
IN2013MU03658A (https=) 2013-11-21 2015-09-25 Akanksha Bindeshwari Prasad Yadav
US10525171B2 (en) 2014-01-24 2020-01-07 The Spectranetics Corporation Coatings for medical devices

Also Published As

Publication number Publication date
CN101801415B (zh) 2015-09-23
BRPI0811319A2 (pt) 2015-02-10
US20230135427A1 (en) 2023-05-04
MX337286B (es) 2016-02-22
US20220354955A1 (en) 2022-11-10
ES2562878T3 (es) 2016-03-08
US9186413B2 (en) 2015-11-17
JP5795606B2 (ja) 2015-10-14
US10376590B2 (en) 2019-08-13
US20150099767A1 (en) 2015-04-09
US11013809B2 (en) 2021-05-25
EP2152315A2 (en) 2010-02-17
HK1143731A1 (zh) 2011-01-14
US20200016270A1 (en) 2020-01-16
JP2014240436A (ja) 2014-12-25
US20150005323A1 (en) 2015-01-01
US11712475B2 (en) 2023-08-01
JP2013139479A (ja) 2013-07-18
AU2008262545B2 (en) 2013-12-05
EP2152315B1 (en) 2016-01-06
CN101801415A (zh) 2010-08-11
MX354603B (es) 2018-03-13
MX2009012781A (es) 2010-07-02
US20180154001A1 (en) 2018-06-07
NZ581862A (en) 2012-06-29
JP2010531807A (ja) 2010-09-30
AU2008262545A1 (en) 2008-12-18
CA2687979A1 (en) 2008-12-18
US20100266655A1 (en) 2010-10-21
WO2008153611A2 (en) 2008-12-18
US9180197B2 (en) 2015-11-10
WO2008153611A3 (en) 2009-07-16
EP2907524A1 (en) 2015-08-19
CA2687979C (en) 2017-07-04
US10010612B2 (en) 2018-07-03

Similar Documents

Publication Publication Date Title
NZ597621A (en) Sustained delivery formulations of risperidone compounds
Abdollahiyan et al. The triad of nanotechnology, cell signalling, and scaffold implantation for the successful repair of damaged organs: An overview on soft-tissue engineering
Cheng et al. Strontium ion-functionalized nano-hydroxyapatite/chitosan composite microspheres promote osteogenesis and angiogenesis for bone regeneration
WO2007038246A3 (en) Solid polymer delivery compositions and methods for use thereof
Azarmgin et al. Polyurethanes and their biomedical applications
Bao et al. 3D biomimetic artificial bone scaffolds with dual-cytokines spatiotemporal delivery for large weight-bearing bone defect repair
WO2009044403A3 (en) Injectable biodegradable polymer compositions for soft tissue repair and augmentation
Lanao et al. Bone response to fast-degrading, injectable calcium phosphate cements containing PLGA microparticles
Ferretti et al. Controlled in vivo degradation of genipin crosslinked polyethylene glycol hydrogels within osteochondral defects
Wu et al. Advancing scaffold‐assisted modality for in situ osteochondral regeneration: a shift from biodegradable to bioadaptable
IL223488A (en) Injectable flow bar preparation containing buprenorphine
JP2013533230A5 (https=)
EA027046B1 (ru) Биоразлагаемая композиция для доставки лекарственных средств, способ ее получения и ее применение
Li et al. Advanced hydrogel material for meniscus repair
MX338373B (es) Composicion antipsicotica inyectable de liberacion controlada.
AU2000202A (en) Methods and compositions for enhanced delivery of bioactive molecules
WO2010005723A3 (en) Drug loaded polymeric nanoparticles and methods of making and using same
EP1786400A4 (en) PHARMACEUTICAL COMPOSITIONS FOR THE CONTROLLED RELEASE OF BIOLOGICAL ACTIVE SUBSTANCES
WO2006050091A3 (en) Bioactive wound dressings and implantable devices and methods of use
Dallaev Smart and biodegradable polymers in tissue engineering and interventional devices: A brief review
WO2008051881A3 (en) Bioabsorbable medical device with coating
Qian et al. Dual-modal imaging and synergistic spinal tumor therapy enabled by hierarchical-structured nanofibers with cascade release and postoperative anti-adhesion
Chen et al. Recent advances in injectable hydrogels for osteoarthritis treatments
Wang Smart materials for tissue engineering: applications
Wang et al. Application and progress of 3D printed biomaterials in osteoporosis

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 13 FEB 2015 BY CPA GLOBAL

Effective date: 20131029

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 FEB 2016 BY CPA GLOBAL

Effective date: 20150116

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 FEB 2017 BY COMPUTER PACKAGES INC

Effective date: 20160119

ASS Change of ownership

Owner name: INDIVIOR UK LIMITED, GB

Effective date: 20160414

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 FEB 2018 BY COMPUTER PACKAGES INC

Effective date: 20170118

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 FEB 2019 BY COMPUTER PACKAGES INC

Effective date: 20180118

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 FEB 2020 BY CPA GLOBAL

Effective date: 20181227

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 FEB 2021 BY CPA GLOBAL

Effective date: 20200102

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 FEB 2022 BY COMPUTER PACKAGES INC

Effective date: 20210119

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 FEB 2023 BY COMPUTER PACKAGES INC

Effective date: 20220117

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 FEB 2024 BY COMPUTER PACKAGES INC

Effective date: 20230117

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 FEB 2025 BY COMPUTER PACKAGES INC

Effective date: 20240117

LAPS Patent lapsed